Optimization of a Liposomal DNase I Formulation with an Extended Circulating Half-Life
Lesly Carolina Penaloza Arias, David N. Huynh, Samuel Babity, Sylvie Marleau, Davide Brambilla
Abstract
Drug delivery systems such as liposomes are widely used to stabilize and increase the plasma half-life of therapeutics. In this article, we have investigated two strategies to increase the half-life of deoxyribonuclease I, an FDA-approved enzyme used for the treatment of cystic fibrosis, and a potential candidate for the reduction of uncontrolled inflammation induced by neutrophil extracellular traps. We demonstrate that our optimized preparation procedure resulted in nanoparticles with improved plasma half-life and total exposure relative to native protein, while maintaining enzymatic activity.
Topics & Concepts
LiposomeCystic fibrosisDrugDeoxyribonuclease IEnzymeChemistryInflammationDrug deliveryPharmacologyBiochemistryMedicineImmunologyInternal medicineDNAOrganic chemistryBase sequenceNeutrophil, Myeloperoxidase and Oxidative MechanismsAdvanced Nanomaterials in CatalysisNanoplatforms for cancer theranostics